Clinical Trials for Ovarian Cancer

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, including ATM-altered cancers and platinum-resistant ovarian cancer, receive the oral ATR kinase inhibitor ART0380 (alnodesertib) alone or with gemcitabine or irinotecan. The ovarian cancer cohort compares ART0380 plus gemcitabine with gemcitabine alone.

ClinicalTrials.gov ID: NCT04657068

A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with mesothelin-expressing recurrent or relapsed advanced ovarian, primary peritoneal, or fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma after at least one systemic therapy receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110. This autologous engineered T-cell therapy targets mesothelin through a KIR-based chimeric receptor with DAP12 signaling.

ClinicalTrials.gov ID: NCT05568680

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors or lymphoma, including disease-specific cohorts defined by ARID1A mutation or BAP1 loss, receive oral tulmimetostat, an investigational EZH2/EZH1 inhibitor that disrupts PRC2-mediated gene repression. A metastatic castration-resistant prostate cancer cohort receives tulmimetostat with enzalutamide.

ClinicalTrials.gov ID: NCT04104776

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients have previously platinum-treated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, or recurrent/progressive endometrial cancer after platinum chemotherapy and anti–PD-1 therapy; ECOG performance status must be 0–1. Treatment is REGN5668, an investigational MUC16×CD28 bispecific antibody that provides tumor-directed T-cell costimulation, alone or with cemiplimab (anti–PD-1), cemiplimab plus fianlimab (anti–LAG-3), or ubamatamab (MUC16×CD3), with or without sarilumab.

ClinicalTrials.gov ID: NCT04590326

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Biomarker-selected adults with recurrent ovarian (including fallopian tube/primary peritoneal) or endometrial cancer receive abemaciclib, a CDK4/6 inhibitor targeting cyclin D–CDK4/6–RB signaling; ovarian cases require CDK4/6 pathway activation, and endometrioid endometrial tumors must be HR-positive without CCNE amplification or RB loss. Hormone receptor–positive tumors may also receive an aromatase inhibitor (anastrozole or letrozole).

ClinicalTrials.gov ID: NCT04469764

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors, measurable disease, and ECOG performance status 0–1 receive AZD5335, a folate receptor alpha–targeted antibody–drug conjugate delivering a topoisomerase I inhibitor. It is studied alone or with the PARP1 inhibitors saruparib or AZD9574, bevacizumab, or carboplatin with or without bevacizumab; module-specific eligibility may apply.

ClinicalTrials.gov ID: NCT05797168

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with advanced solid tumors, measurable disease, and ECOG performance status 0–1. All participants receive ixotatug vedotin (TORL-1-23), an investigational claudin-6–targeting antibody–drug conjugate that delivers the microtubule-disrupting payload monomethyl auristatin E.

ClinicalTrials.gov ID: NCT05103683

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients have recurrent or progressive advanced ovarian, fallopian tube, or primary peritoneal cancer after platinum therapy, or recurrent endometrial cancer after platinum chemotherapy and anti–PD-1 therapy with MUC16 expression in at least 25% of tumor cells. Treatment is ubamatamab, an investigational MUC16×CD3 bispecific antibody that recruits T cells to kill tumor cells, alone or with the PD-1 inhibitor cemiplimab.

ClinicalTrials.gov ID: NCT03564340

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with recurrent or refractory solid tumors after standard treatment may be eligible if they are HLA-A*02:01-positive, have PRAME-expressing tumors and measurable disease, and have ECOG performance status 0–1. After lymphodepletion, they receive autologous T cells engineered with a receptor targeting PRAME presented by HLA-A*02:01 (IMA203 or CD8-enhanced IMA203CD8); some cohorts also receive IL-2 or, with IMA203, the PD-1 inhibitor nivolumab.

ClinicalTrials.gov ID: NCT03686124

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or recurrent measurable solid tumors and no established beneficial treatment option receive BP1001-A, an investigational liposomal antisense oligonucleotide targeting Grb2. An expansion cohort with recurrent or persistent ovarian, fallopian tube, primary peritoneal, or endometrial cancer receives BP1001-A plus paclitaxel.

ClinicalTrials.gov ID: NCT04196257